Timothy Lynch Insider Profile
4 Followers
Timothy Lynch, Ten Percent Owner at AEON Biopharma, holds 6.50M shares in AEON Biopharma (Ticker: AEON), holds 240.00K shares in Aradigm (Ticker: ARDMQ), holds 0.00 shares in Vaxart (Ticker: VXRT). Most recently, Timothy Lynch Bought ― shares of AEON Biopharma on Aug 21, 2026 for an estimated value of $241.50K.
Timothy Lynch has not reported sufficient informative transactions and therefore cannot be ranked.
Time Frame
Compare to
Insider Holdings
Insider Roles
Roles that Timothy Lynch holds in companies
Most Profitable Insider Trade
The most profitable trade made by Timothy Lynch
Timothy Lynch's Trading History
AEON Biopharma
Aug 21, 2026
Ten Percent Owner
Informative Buy
241.50K
$1.65M
Aradigm
―
―
―
$11.04K
Vaxart
Nov 18, 2009
Director
Informative Sell
20.00K
$0.00
Insite Vision
―
―
―
$0.00
List of latest transactions for each holding click on a transaction to see Timothy Lynch's performance on stock
You May Also Like
Timothy Lynch insider profile FAQ
What is the percentage of profitable transactions made by Timothy Lynch?
The percentage of profitable transactions made by Timothy Lynch is ―.
What is the average return per transaction made by Timothy Lynch?
The average return per transaction made by Timothy Lynch is ―.
What stocks does Timothy Lynch hold?
Timothy Lynch holds: AEON, ARDMQ, VXRT, INSV stocks.
What was Timothy Lynch’s latest transaction?
Timothy Lynch latest transaction was an Informative Buy of $241.50K.
What was Timothy Lynch's most profitable transaction?
Timothy Lynch’s most profitable transaction was an Informative Sell of VXRT stock on November 18, 2009. The return on the trade was -6.00%.
What is Timothy Lynch's role in AEON Biopharma?
Timothy Lynch's role in AEON Biopharma is Ten Percent Owner.
How can I follow the stock ratings of top corporate insiders?
Head over to our Expert Center to see a list of the Top 100 corporate insiders and follow the corporate insiders of your choice. Visit their profiles for more details about their stock transactions and see how they perform on a stock-by-stock basis.